Treatment of Chronic Renal Failure With Adipose Tissue-derived Mesenchymal Stem Cells
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03321942|
Recruitment Status : Recruiting
First Posted : October 26, 2017
Last Update Posted : October 26, 2017
|Condition or disease||Intervention/treatment||Phase|
|Mesenchymal Stem Cells Chronic Kidney Diseases Renal Interstitial Fibrosis||Drug: Treatment group Drug: Control group||Not Applicable|
|Study Type :||Interventional|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Biological Characteristics of Adipose Tissue-derived Mesenchymal Stem Cells and Its Role in the Treatment of Chronic Renal Failure|
|Actual Study Start Date :||January 1, 2017|
|Estimated Primary Completion Date :||December 31, 2018|
|Estimated Study Completion Date :||December 31, 2018|
Active Comparator: Treatment group
Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure.
Drug: Treatment group
Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.
Other Name: Stem cells treatment group
Placebo Comparator: Control group
Treatment of chronic renal failure patients with conventional methods.
Drug: Control group
Conventional treatment were used to treat patients with chronic renal failure.
Other Name: Conventional treatment group
- serum creatinine [ Time Frame: after 3 months of adipose tissue-derived mesenchymal stem cells treatment ]intravenous blood sampling
- glomerular filtration rate [ Time Frame: after 3 months of adipose tissue-derived mesenchymal stem cells treatment ]emission computed tomography
- apparent relaxation rate [ Time Frame: after 3 months of adipose tissue-derived mesenchymal stem cells treatment ]blood oxygen level dependent magnetic resonance imaging
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03321942
|Contact: Dong Sun, MDfirstname.lastname@example.org|
|The Affiliated Hospital of Xuzhou Medical University||Recruiting|
|Xuzhou, Jiangsu, China, 221000|
|Contact: Dong Sun, MD 15862158578 email@example.com|
|Study Director:||Dong Sun, MD||Affiliated Hospital of Xuzhou Medical University|